ArticleCancer prevention research (Philadelphia, Pa.)2026
Proteomic Analysis of Sphingolipid Metabolic Enzymes with Risk of Bladder Cancer Incidence and Mortality in the Atherosclerosis Risk in Communities Study.
Article in Cancer prevention research (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lipid metabolism is regarded as a hallmark of cancer. Sphingolipids, a family of structural and signaling lipids, have antiproliferative (ceramides) or prosurvival [sphingosine 1-phosphate (S1P)] functions. The positive association between statin use and bladder cancer, unlike other cancers, suggests that lipid metabolism not affected by HMG-CoA reductase inhibition may contribute uniquely to this cancer. We conducted a hypothesis-generating study investigating associations between plasma sphingolipid metabolic enzymes and bladder cancer incidence and mortality in the Atherosclerosis Risk in Communities study. Among 10,129 men and women with proteomic profiling of plasma collected in 1993 to 1995, 158 incident bladder cancer cases and 47 bladder cancer deaths were ascertained over a median of 20 years of follow-up (164,013 person-years). Cox regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for protein tertiles adjusted for age, race, sex, and known cancer risk factors, including smoking status, pack-years smoked, and cholesterol-lowering medication use. Of the six sphingolipid enzymes, sphingosine kinase 1 (SPHK1), involved in S1P synthesis, was associated with an increased risk of bladder cancer incidence [tertile 3 (T3) vs. T1: HR, 1.74; 95% CI, 1.15-2.63; P trend = 0.008] and bladder cancer mortality (T3 vs. T1: HR, 2.39; 95% CI, 1.02-5.61; P trend = 0.06). Associations for incidence were attenuated in lagged analyses, suggesting potential reverse causation, whereas associations for mortality were unchanged. Our findings suggest that sphingolipid metabolism, specifically enzymes involved in S1P synthesis, may contribute to bladder cancer etiology, with stronger associations in subgroups with lower cholesterol. These findings motivate confirmatory investigation of plasma S1P in relation to bladder cancer outcomes. PREVENTION RELEVANCE: We report a consistent positive association for SPHK1, involved in S1P metabolism, and bladder cancer risk and mortality in our prospective study. Stronger positive associations for SPHK1 were noted in subgroups with lower cholesterol, reflecting a shift in structural and/or signaling lipids to influence bladder cancer initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.